May 042012
Antony (France), 4 May 2012 – Stallergenes S.A (Euronext Paris CAC small) today announced results of a clinical study (VO67.10) of its house dust mites sublingual immunotherapy tablet, conducted in an Environmental Exposure Chamber…
Excerpt from:
Stallergenes Announces Positive Clinical Results for Its House Dust Mites Immunotherapy Tablet